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Protocol
AbstrAct
Introduction Bipolar disorder is an often disabling mental 
illness with a lifetime prevalence of 1%–2%, a high risk of 
recurrence of manic and depressive episodes, a lifelong 
elevated risk of suicide and a substantial heritability. The 
course of illness is frequently characterised by progressive 
shortening of interepisode intervals with each recurrence 
and increasing cognitive dysfunction in a subset of 
individuals with this condition. Clinically, diagnostic 
boundaries between bipolar disorder and other psychiatric 
disorders such as unipolar depression are unclear 
although pharmacological and psychological treatment 
strategies differ substantially. Patients with bipolar 
disorder are often misdiagnosed and the mean delay 
between onset and diagnosis is 5–10 years. Although 
the risk of relapse of depression and mania is high it is 
for most patients impossible to predict and consequently 
prevent upcoming episodes in an individual tailored way. 
The identification of objective biomarkers can both inform 
bipolar disorder diagnosis and provide biological targets 
for the development of new and personalised treatments. 
Accurate diagnosis of bipolar disorder in its early stages 
could help prevent the long-term detrimental effects of 
the illness. The present Bipolar Illness Onset study aims 
to identify (1) a composite blood-based biomarker, (2) a 
composite electronic smartphone-based biomarker and (3) 
a neurocognitive and neuroimaging-based signature for 
bipolar disorder.
Methods and analysis The study will include 300 
patients with newly diagnosed/first-episode bipolar 
disorder, 200 of their healthy siblings or offspring and 100 
healthy individuals without a family history of affective 
disorder. All participants will be followed longitudinally with 
repeated blood samples and other biological tissues, self-
monitored and automatically generated smartphone data, 
neuropsychological tests and a subset of the cohort with 
neuroimaging during a 5 to 10-year study period.
Ethics and dissemination The study has been approved 
by the Local Ethical Committee (H-7-2014-007) and 
the data agency, Capital Region of Copenhagen (RHP-
2015-023), and the findings will be widely disseminated 
at international conferences and meetings including 
conferences for the International Society for Bipolar 
Disorders and the World Federation of Societies for 
Biological Psychiatry and in scientific peer-reviewed 
papers.
Trial registration number NCT02888262.
InTroducTIon
Biomarkers in bipolar disorders
Bipolar disorder is a disabling mental illness 
with a lifetime prevalence of 1%–2%, a high 
risk of recurrence of manic and depressive 
episodes, a lifelong elevated risk of suicide 
and a substantial heritability of 60%–80%.1 
Bipolar disorder is often conceptualised 
as a progressive disorder with increasing 
risk of recurrence for every new affective 
episode2–5 and with increasing cognitive 
disabilities during the course of illness.6–9 
Clinically, diagnostic boundaries between 
bipolar disorder and other psychiatric 
Strengths and limitations of this study
 ► The Bipolar Illness Onset (BIO) study is the first 
study aiming to identify (1) a composite blood-based 
biomarker, (2) a composite electronic smartphone-
based biomarker and (3) a neurocognitive signature 
for bipolar disorder.
 ► The same biomarkers will be measured longitudinally 
in newly diagnosed/first-episode patients with 
bipolar disorder and their healthy first-generation 
relatives.
 ► The BIO study will be performed by an experienced 
international research group, combining expertise 
from all areas of the study.
 ► Extensive initial assessment of  study procedures 
may result in selection of participants who are 
intrinsically positive towards clinical research
 ► Confounding effects of psychotropic medication 
may influence results.
 ► Lack of randomised interventions may limit causal 
interpretations of the results.
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disorders such as unipolar disorder are unclear although 
some pharmacological and psychological treatment strat-
egies differ substantially. Patients with bipolar disorder 
are often misdiagnosed as having unipolar disorder, tran-
sient psychosis, reaction to stress/adjustment disorder 
or psychoactive substance abuse,10 and the mean delay 
between onset and diagnosis is 5–10 years.11 Although 
the risk of relapse of depression and mania is high, it is 
for most patients impossible to predict and consequently 
prevent upcoming episodes in an individual tailored way. 
The identification of objective biomarkers as measures 
of pathophysiological processes can both inform bipolar 
disorder diagnosis and provide biological targets for 
the development of new and personalised treatments.12 
Accurate diagnosis of bipolar disorder in its early stages 
could help prevent the long-term detrimental effects of 
the illness.
Recently, promising results have been presented 
regarding a diagnostic test for unipolar depression 
comprising levels of nine biomarkers in peripheral 
blood.13 Although the nature of bipolar disorder seems 
more biologically driven than the nature of major depres-
sion with a higher heritability, there has been no or few 
attempts to identify a similar composite biomarker for 
bipolar disorder.
onset of illness and staging in bipolar disorder
Although the course of illness is heterogeneous, there 
is a body of evidence for clinical progression on average 
of unipolar and bipolar disorders as increasing number 
of affective episodes seem associated with (1) increasing 
risk of recurrence, (2) increasing duration of episodes, 
(3) increasing symptomatic severity of episodes, (4) 
decreasing threshold for developing episodes and (5) 
increasing risk of developing dementia.9 It is likely that this 
clinical progression with deteriorating effects of affective 
episodes and duration of illness is associated with neurobi-
ological changes over the course of illness. Unfortunately, 
results of all longitudinal studies on the biology of bipolar 
disorder are hitherto hampered by three major limita-
tions: (1) Only few studies have recruited patients with 
bipolar illness from onset of the illness and most of these 
have used first-onset mania as inclusion criteria thereby 
excluding patients with a hypomanic episode (bipolar 
disorder, type II). As the biology of bipolar disorder—
based on cross-sectional studies—seems to change over 
the course of illness from first episode to first relapse 
and recurrent relapses to an unremitting or rapid cycling 
course,14–18 this is a major limitation in our knowledge 
internationally, (2) the number of patients included in 
prior studies is less than 200, which is a limitation taking 
the heterogeneity of bipolar disorder into account (eg, 
bipolar disorder types I and II may have different biology, 
and so on), and (3) the prospective follow-up period is 
less than a few years in all studies.
In the Bipolar Illness Onset (BIO) study, we will estab-
lish a large cohort compromising three subcohorts that 
will be followed long term with systematic diagnostic, 
blood-based biomarkers, smartphone data and cognitive 
and brain imaging assessment. The three subcohorts will 
consist of: (1) patients with newly diagnosed/first-episode 
bipolar disorder and (2) their healthy first-generation 
siblings and offspring and (3) healthy individuals without 
a family history of affective disorder.
overall aims
1. To identify a composite blood-based biomarker 
measure as well as a composite electronic smartphone-
based biomarker from onset of bipolar disorder 
during progression and in later stages.
2. To investigate if the composite blood-based biomarker 
measure and electronic smartphone-based biomarker 
identified among patients with bipolar disorder 
predict onset of illness (depression or mania) among 
these patients’ healthy first-generation siblings and 
offspring.
3. By applying an integrated systems approach, to identify 
patterns of ‘cerebral signatures’ across neurocircuitry 
and cognitive levels and to validate the composite 
blood-based biomarker and electronic smartphone-
based biomarkers against these biosignatures.
4. To investigate long-term developmental trajectories in 
neurocognitive function and brain imaging from the 
high-risk state to onset of bipolar disorder following 
first relapse and recurrent relapses and in the late 
stage with an unremitting, multiepisode or rapid 
cycling course.
5. To investigate whether the course of illness is 
progressive on average in bipolar disorder and to 
identify corresponding changes in biomarkers during 
the course of illness within BIO-1 to BIO-4.
MeThods and analysIs
overall methods
The BIO study is a long-term cohort study that started 
on April 2015 and planned to include 300 newly diag-
nosed/first-episode patients with bipolar disorder from 
the Copenhagen Affective Disorder Clinic, 200 of these 
patients’ healthy first-generation relatives and 100 healthy 
individuals without a first-generation family history of 
affective disorders.
The copenhagen affective disorder clinic
The Copenhagen Affective Disorder Clinic is a mood 
disorder clinic that provides treatment service for patients 
with newly diagnosed/first-episode bipolar disorder.19 The 
Copenhagen Affective Disorder Clinic receives patients 
from the entire Capital Region of Denmark covering a 
catchment area of 1.6 million people and all psychiatric 
centres in the region. All patients referred to the Clinic 
as newly diagnosed/first-episode patients, that is, onset 
of first manic or hypomanic episode or when the ICD-10 
(International Statistical Classification of Diseases and 
Related Health Problems 10th Revision) diagnosis of 
bipolar disorder is made for the first time, will routinely 
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be asked for inclusion in the BIO study. Nearly all patients 
treated in the Clinic have a diagnosis of bipolar disorder 
type I or type II whereas patients with bipolar disorder-not 
otherwise specified or patients with cyclothymia are not 
treated in the Clinic and consequently not included in 
the BIO study.
recruitment of the three cohorts
1. Three hundred patients (aged 15–70 years) referred 
to the Copenhagen Affective Disorder Clinic as 
newly diagnosed/first-episode patients with bipolar 
disorder, that is, onset of first manic or hypomanic 
episode or when the diagnosis of bipolar disorder 
is made for the first time. The Clinic receives more 
than 100 newly diagnosed/first-episode patients with 
bipolar disorder each year and we expect that nearly 
all will accept participation in the BIO study as this 
implies an extensive clinical evaluation.
2. Two hundred first-generation relatives (siblings and 
children aged 15–40 years) to the recruited newly 
diagnosed/first-episode patients with bipolar disorder.
3. One hundred age and gender-matched healthy 
individuals without a first-generation family history 
of affective disorders recruited among blood donors 
from the Blood Bank at Rigshospitalet, Copenhagen, 
as in prior studies.
diagnostic assessments at inclusion
The initial diagnostic assessment will be done using the 
Structured Clinical Interview for DSM-IV-TR Axis I Disor-
ders20 categorising patients into bipolar disorder type 
I or type II as part of daily praxis by the experienced 
specialists in psychiatry during the patients’ 2-year stay 
in the Copenhagen Affective Disorder Clinic. This clin-
ical diagnosis of bipolar disorder will be confirmed in a 
semistructured research-based interview using the Sched-
ules for Clinical Assessment in Neuropsychiatry (SCAN) 
providing an ICD-10 diagnosis.21 There will be no attempt 
to balance the prevalence of bipolar subtypes in the BIO 
study.
Follow-up
Besides the assessments at inclusion, patients will be 
assessed during remitted, depressive and manic/mixed 
phases. Patients and healthy control individuals will be 
initially assessed face-to-face and at least every year during 
the first 4 years and after this, every second year for 5 years.
As part of daily clinical praxis in Copenhagen Affec-
tive Disorder Clinic and as part of the BIO-2 substudy, all 
patients will get access to a smartphone app for electronic 
continuous monitoring of illness activity during a 5-year 
follow-up period (see substudy BIO-2). Additionally, 
research assistants will contact all participants every third 
month to identify upcoming episodes/onset of illness 
and to ensure continued participation in the BIO study. 
At each assessment, the present clinical state (remission, 
manic, hypomanic, depressive, mixed episode) of all 
participants will be established according to ICD-10. The 
severity of depressive and manic symptoms (if present) 
will be assessed using the 17-item Hamilton Depression 
Rating Scale (HAMD-17)22 and the Young Mania Rating 
Scale (YMRS)23 with a time period of 3 days applied. 
Remission is defined as score of <7 on the HAMD-17 and 
the YMRS. In this way, upcoming episodes and onset of 
illness (for healthy individuals) will be assessed with great 
certainty.
Based on prior findings,2 3 19 it is estimated that patients 
will develop four to five affective episodes on average 
during the follow-up period, that is, relapse or recur-
rence, defined as above. It estimated that 20%–30% of 
the healthy first-generation relatives will develop onset of 
affective illness compared with 2%–5% among the healthy 
individuals without a first-generation family history of affec-
tive disorders.24 25 Finally, linkage to Danish nationwide 
register-based data will be included for all individuals on 
psychiatric hospitalisations, prescribed medication and 
socioeconomic variables during the 5-year follow-up.
Investigations
We will include state-of-the-art methods within clinical 
assessment as well as biomarkers including a range of new 
methods:
1. clinical assessments using the Hamilton Depression 
Scale-17 items (HAMD-17),22 the YMRS,23 the 
Functional Assessment Short Test (FAST) (a measure 
of psychosocial function)26;
2. questionnaires including the Hypomania Check list,27 
Standardized Assessment of Personality-Abbreviated 
Scale,28 the WHO (Five) well-being index29 and the 
Verona Satisfaction Scale-Affective Disorder30;
3. standardised fasting blood tests for a large number 
of potential biomarkers (see the BIO-1, Biological 
tests section);
4. spot urine samples for oxidative generated damage to 
DNA and RNA;
5. hair cortisol as a valid and reliable index of long-term 
systemic cortisol levels31;
6. combined heart rate and movement sensor mounted 
at the thorax (Actiheart32 33);
7. daily electronic smartphone-based self-monitoring of 
depressive and manic symptoms;
8. daily electronic smartphone-based automatically 
generated data (eg, data on phone usage, social 
activity and physical activity);
9. neuropsychological assessment (only during full or 
partial remission);
10. structural MRI focusing on prefrontal cortex and 
hippocampus as well as functional MRI (fMRI) (only 
during full or partial remission).
Clinical assessments will be performed by six PhD 
students (master's degree as a Medical Doctor or psychol-
ogist). They will be certified in a PhD training course in 
the SCAN interview and will be trained in using rating 
scales (HAMD-YMRS, FAST). Inter-rater sessions super-
vised by senior clinicians from the Copenhagen Affective 
Disorder Clinic and senior researchers in the BIO study 
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will be conducted among the researchers at regular time 
points during the entire study period.
The BIO study includes four separate but interacting 
substudies (BIO-1, BIO-2, BIO-3, BIO-4), as illustrated in 
table 1 with specified aims, background and theoretical 
basis, and methods, as described in the following. Back-
ground and reasons for selection of putative biomarkers 
is an iterative process presented in each substudy. Never-
theless, as the area of potential biomarkers is constantly 
evolving and as the substudies cover four different areas, 
the research protocol does not include systematic reviews 
of the literature.
BIo-1: peripheral blood-based biomarker in bipolar disorder
Aims
To identify a composite blood-based biomarker that (1) 
discriminates individuals with bipolar disorder from 
healthy control individuals, (2) discriminates between 
manic, depressive and remitted states, (3) predicts 
emerging affective episodes, and (4) to validate the 
composite blood-based biomarker against the smart-
phone-based biomarker, and the neurocognitive and 
brain imaging signature, and (5) to investigate the change 
in individual biomarkers as well as the composite blood-
based biomarker following onset of first manic episode, 
during successive relapses and in the end late stages of 
the illness.15
Background and theoretical basis
In a series of meta-analyses, we concluded that although 
a number of candidate peripheral biomarkers related 
to neuroplasticity, inflammation, oxidative stress and 
gene expression seem promising, findings are limited 
by poor study designs, small cross-sectional samples, 
lack of adjustment for important confounders related to 
most peripheral biomarkers and poor laboratory meth-
odology.34–37 Because of high interindividual variation 
in peripheral biomarkers, assessment of intraindividual 
alterations from onset of illness through different affec-
tive phases and into the late illness stage is necessary to 
identify clinically relevant and valid biomarkers, necessi-
tating a longitudinal study design.35 38
We have in two longitudinal studies with repeated 
assessments of patients with bipolar disorder during 
affective states (manic/mixed, depressive and euthymic) 
and healthy control individuals found that brain-derived 
neurotrophic factor (BDNF),39 increased oxidative DNA 
and RNA damage40 41 and decreased mRNA expression of 
the PTGDS gene encoding the prostaglandin D synthase 
enzyme42 are markers related to the illness trait in bipolar 
disorder. The level of the cytokines IL-6 and IL-18 (inter-
leukin) was related to manic episodes only and the activity 
of GSK-3beta varied with affective states,43 suggesting 
that these may be state markers.44 These results have 
contributed to the research area of biomarkers in bipolar 
disorder, moving the area closer towards identifying clini-
cally applicable biomarkers.
Nevertheless, it is unlikely that one single biomarker 
will provide a useful diagnostic tool; instead, a composite 
of several relevant biomarkers appears as more viable 
approach.45 Recently, promising results have been 
presented regarding a diagnostic test in unipolar depres-
sion comprising serum levels of nine individual biomarkers 
in peripheral blood.13 Similarly, preliminary studies have 
suggested composite biomarkers for bipolar disorder.46–48 
We identified a composite biomarker consisting of gene 
expression from 19 candidate genes for bipolar disorder 
that accurately discriminated patients with bipolar disorder 
from healthy control individuals.46 Thus, such approaches 
highly increase the chances of obtaining a high specificity 
and sensitivity of the composite blood-based biomarker.46–48
In order to establish relevant markers of risk and 
markers related to illness stage, it is necessary to include 
assessment before onset of illness and during first and 
recurrent relapses and in the late stages of the illness 
according to the staging model of bipolar disorder.49 
Further, the study of early-onset individuals is necessary to 
evaluate biomarker levels without influence from medica-
tion, which may otherwise limit the validity of identified 
biomarkers.
Methods
BIO-1 will include repeated clinical assessments and 
corresponding samples of blood and other tissues among 
Table 1 Overview of the longitudinal assessments during risk periods and following onset of bipolar disorder in the four 
substudies of the BIO study
Course
Healthy first-generation 
relatives First episode Remission First relapse Remission
Second 
relapse Others
BIO-1 x x x x x x x
BIO-2 x x x x x x x
BIO-3 x x x x
BIO-4 x x x x x x x
BIO-1: Peripheral blood-based biomarker in bipolar disorder.
BIO-2: Smartphone-based electronic biomarker in bipolar disorder.
BIO-3: Neurocognitive and brain imaging signatures in bipolar disorder.
BIO-4: At risk or prodromal phase for bipolar disorder.
BIO, Bipolar Illness Onset study.
group.bmj.com on August 2, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 5Kessing LV, et al. BMJ Open 2017;7:e015462. doi:10.1136/bmjopen-2016-015462
Open Access
the 300 newly diagnosed/first-episode patients with 
bipolar disorder, the 200 first-generation relatives and the 
100 healthy individuals without a first-generation family 
history of affective disorder.
We will estimate a composite blood-based biomarker 
based on a number of individual markers including 
BDNF, neutrophin-3, five different cytokines, gene expres-
sion, additional 30 candidate genes and other potential 
biomarkers (see the Biological tests section), and iden-
tify the composite biomarker that correlates best with 
affective states and Hamilton Depression Rating Scale 
and YMRS scores of depression and mania, respectively. 
A final blood-based biomarker will be chosen based on its 
ability to (1) discriminate patients with bipolar disorder 
from healthy control individuals and to (2) discriminate 
between manic, depressive and remitted states in bipolar 
disorder.
Laboratory procedures
We will obtain careful standardisation of blood sampling 
and laboratory analysis by obtaining blood samples in a 
fasting state and in a 1-hour interval in the morning. At 
the same day as blood sampling, smoking status, alcohol 
use, body mass index, menstrual cycle, and so on will be 
assessed. Blood sampling and all phases of laboratory 
processing for plasma and DNA/RNA analyses will be 
done at the Department of Clinical Biochemistry, Rigshos-
pitalet, using standard operational methods conducted 
by a team of technicians blinded with respect to partic-
ipant status. All plasma samples will be stored at −80°C. 
The BIO study will include a total of 2400 blood samples: 
300 patients × 5 + 200 healthy first-generation relatives 
× 3 + 100 healthy participants without a first-generation 
family history × 3.
Biological tests
We will use a multianalyte panel including a large 
number of potential biomarkers such as plasma levels of 
Neutrophins3, GSK-3, ß-amyloid Aß40 and Aß42, BDNF, 
inflammatory markers, high-sensitive C-reactive protein, 
lipoproteins (very-low-density lipoprotein, low-den-
sity lipoprotein, high-density lipoprotein) and specific 
apolipoproteins (eg, apoE, apoA-I, apoA-II and apoM) 
as potential markers of low-grade inflammation partic-
ularly salient in the early stages of bipolar disorder. 
Total RNA, microRNA, genomic DNA and histones are 
isolated from peripheral blood mononuclear cells. Gene 
expression and alternative slicing of RNA transcripts 
are analysed using array real-time reverse transcrip-
tase quantitative PCR and next-generation sequencing. 
Epigenetic modifications of the DNA (eg, methylation) 
are measured using antibody-based methods or bisul-
phite treatments in combination with next-generation 
sequencing. The genomic positions of histones with 
specific modifications are detected using chromatin 
immunoprecipitation sequencing. The degree of histone 
modifications is measured by semiquantitative anti-
body-based detection.
Measurements of DNA and RNA damage by oxidation 
are obtained from spot urine samples and analysed using 
ultra performance liquid chromatography and mass spec-
trometry.
Hair cortisol will be included as a valid and reliable 
index of long-term systemic cortisol levels.31
We will report on these individual biological tests 
including comparing patients, first-degree relatives and 
healthy control individuals, when appropriate. The 
BIO study sample of 600 participants is rather small for 
genetic analyses discriminating patients with bipolar 
disorder from healthy controls but some genetic anal-
yses, including the CACNA1C gene, can be conducted 
in cooperation with national and international genetic 
network groups.
Statistical analyses
Data represent repeated measures within and between 
individuals and will be analysed using a combination of 
generalised linear mixed models, integrated data anal-
ysis and penalised regression approaches to facilitate the 
combined feature selection and prediction of the available 
high-dimensional data. Integrative data analysis ensures 
that we are able to identify an improved composite blood-
based biomarker since data from different molecular 
levels are combined in a simultaneous analysis that closely 
resembles the biological system.50 51 Further, we will use 
cross validation or alternatively split sample designs in the 
development and validation of the composite biomarker. 
Finally, if possible we will evaluate the biomarker(s) in 
external non-Danish data sets in collaboration with other 
international researchers.
A general principle that pertains to statistical analyses 
of all four substudies is the ‘intention to treat’ principle. 
Accordingly, participants who during follow-up get a 
diagnosis with a higher diagnostic validity than bipolar 
disorder (ie, a lower ICD-10 diagnostic number, DF00, 
DF10 and DF20) that may substantially influence the 
biomarker measures are included in the analyses until 
onset of symptoms from the disorder but excluded from 
subsequent analyses. These disorders include significant 
neurological disorders such as dementia, stroke, brain 
tumour, multiple sclerosis, Parkinson’s disease as well as 
disorders due to significant psychoactive substance use 
and schizophrenia.
Furthermore, in all four substudies, the problem of 
missing data will be alleviated by the use of mixed effect 
model (for longitudinal measurements) and multiple 
imputations using chained equations when applicable. If 
possible, joint modelling will be considered, depending 
on the missing mechanism observed.
Statistical power
The study has a power of 80% to detect a minimum 
increment of 6.5 percentage points in sensitivity if we 
assume that the existing diagnostic tools have a sensi-
tivity of 70% to diagnose bipolar disorder for a patient 
who has the disorder (see ref 52). Thus, if the composite 
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biomarker score increases the sensitivity by a minimum 
of 6.5 percentage points then we have a power of 80% to 
detect that increase based on 300 patients with bipolar 
disorder using a one-sided exact binomial test (for fixed 
specificity).
BIo-2: smartphone-based electronic biomarker in bipolar 
disorder
Aims
To identify a composite smartphone-based electronic 
biomarker that (1) discriminates patients with bipolar 
disorder from healthy control individuals, (2) discrimi-
nates between manic, depressive and remitted states, (3) 
predicts emerging affective episodes, and (4) to inves-
tigate the change in the composite smartphone-based 
biomarker following onset of first manic episode, during 
successive relapses and in the end stages of the illness as 
according to the staging system by Berk et al.15
Background and theoretical basis
Recently, electronic self-monitoring of the severity of 
depressive and manic symptoms using text messages 
has been suggested as an easy and inexpensive way to 
identify early signs of affective episodes, providing oppor-
tunities for mental healthcare providers to intervene 
shortly after prodromal symptoms first appear.53 We have 
in the MONARCA project developed and tested a smart-
phone-based electronic monitoring system including daily 
subjective self-assessments of illness activity in bipolar 
disorder as well as a bidirectional feedback loop between 
the patient and clinicians (the MONARCA system54–58). 
Using the MONARCA system, fine-grained electronic data 
were collected during everyday life in naturalistic settings in 
patients with bipolar disorder. The MONARCA system was 
reported highly useable and useful by patients with bipolar 
disorder with a high self-assessment adherence (87%–
95%), and the patients reported that the MONARCA system 
helped them to better manage their disease.54 55 Further, 
the severity of depressive and manic symptoms was found 
to correlate with automatically generated smartphone data 
including (1) physical activity as reflected by the number 
of changes in cell tower ID per day,59 (2) social activity as 
reflected by the number of incoming and outgoing calls 
per day, the duration of incoming and outgoing calls per 
day and the number of outgoing text messages per day,60 
and (3) voice features collected during phone calls.61 
Although these findings are encouraging there is a need 
to integrate self-monitored smartphone data with automat-
ically generated smartphone data on social and physical 
activities, speech and sleep into one composite smart-
phone-generated electronic biomarker measure. This 
composite measure should be modelled to (1) discrimi-
nate patients with bipolar disorder from healthy control 
individuals, (2) have a high correlation with depressive 
and manic symptoms, (3) discriminate between euthymic, 
manic and depressive states and (4) early predict emerging 
affective episodes for the individual patient to increase the 
possibility for early intervention.
To validate smartphone-based measures of phys-
ical activity and sleep, a subset of patients will wear a 
combined heart rate and movement sensor mounted at 
the thorax that has been shown to correlate with mood 
symptoms and affective states and differentiate between 
patients and controls (Actiheart32 33) like other wearable 
actigraphs.62–64
Methods
All newly diagnosed/first-episode patients will have 
access to a smartphone-based system (Monsenso that is 
developed from the MONARCA system) for continuous 
self-monitoring as well as fine-grained automatically 
monitoring of behavioural activity and early identification 
of emerging affective episodes during the first 2 years and 
following relapse of episodes during a 5-year follow-up 
period.
Data analyses
In contrast to data in BIO-1, data in BIO-2 represent 
big data collected on a daily basis within individuals. We 
will use hierarchical Bayesian predictive models that can 
handle big data through sampling and visualisation tech-
niques that summarise data.
BIo-3: neurocognitive and brain imaging signatures in 
bipolar disorder
Aims
(1) To identify an integrated brain-based biomarker of 
bipolar disorder including neurocognitive and neuroim-
aging measures tapping into ‘hot’ (ie, emotion laden) 
and ‘cold’ (non-emotional) cognition, (2) to examine 
whether the degree of abnormality in these measures 
predicts illness onset in the high-risk group and/or 
relapse in the patient group, (3) to identify developmental 
trajectories in ‘hot’ and ‘cold’ cognitive dysfunction and 
to identify structural MRI and fMRI correlates in bipolar 
disorder via longitudinal assessments of high-risk indi-
viduals to remission after onset of first manic episode 
and following successive relapses, and (4) to identify 
associations between aberrant ‘hot’ and ‘cold’ neurocog-
nitive functions, structural and functional brain changes 
and the composite blood-based and smartphone-based 
biomarkers. Such ‘integrated systems approach’ involving 
identification of patterns of biomarkers (biosignatures) 
across these multiple levels of investigation is considered 
imperative for deeper understanding of the dimensions 
of underlying pathophysiological processes in bipolar 
disorder.12
Background and theoretical basis
Results from a number of meta-analyses of a large 
number of cross-sectional studies of patients with bipolar 
disorder in remission suggest trait-related ‘cold’ cogni-
tive deficits in attention/processing speed, memory and 
executive function compared with healthy controls65–68 
that correlate with everyday functioning.69 Cross-sec-
tional comparison of patients at different illness stages 
revealed more pronounced cognitive deficits during late 
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stage compared with early stage in line with the staging 
hypothesis of bipolar disorder.70 However, there are only 
a few longitudinal studies of neuropsychological func-
tioning with small sample sizes (12 studies including a 
total of 152 patients with bipolar disorder71). A meta-anal-
ysis of these studies found no support for a progressive 
nature of cognitive deficits.71 However, results from 
these studies are hampered by a number of limitations 
including small sample sizes, short follow-up (mean 
follow-up period of 4.6 years) and high attrition rates (up 
to 45%).71 Consequently, it is unclear whether cognitive 
function assessed with neuropsychological tests deterio-
rates with the number and duration of illness episodes in 
bipolar disorder although epidemiological studies consis-
tently revealed increased increasing risk of dementia with 
the number of episodes7 (see also ref 9). Risk of devel-
oping dementia long-term6 8 72–74 and there are is some 
evidence for 
Deficits in ‘hot’ cognition are closely linked to 
emotional disturbances75 and difficulties in socioemo-
tional behaviour and interpersonal relations in bipolar 
disorder.76 ‘Hot’ cognition abnormalities in bipolar 
disorder have been observed within three domains: (1) 
emotional processing, (2) reward processing and (3) 
emotion regulation (reviews in refs 77 78).
Results from a large number of cross-sectional struc-
tural imaging studies suggest that patients also show 
increased lateral ventricular volumes and greater prev-
alence of white matter hyperintensities.79 While these 
findings are rather unspecific, studies also suggest 
that treatment with lithium increases the grey matter 
volume of prefrontal cortex, amygdala and hippo-
campus.79 In addition, a number of functional imaging 
studies suggest that bipolar disorder is associated with 
abnormalities within fronto-limbic-subcortical struc-
tures.38
As long-term, integrative studies are lacking, it is 
unclear how neurocognitive and brain imaging abnor-
malities correlate with the staging of bipolar disorder, 
illness progression and treatment38 80 or with changes in 
biological markers such as neurotropic, inflammatory 
and oxidative stress markers.81 82
Methods
Using a comprehensive neurocognitive test battery, we 
will assess all participants from the three groups (patients 
with bipolar disorder, first-generation relatives and 
healthy individuals without a family history of affective 
disorders). Patients will be followed from first onset of 
affective disorder and during successive periods of remis-
sion or at an annual basis (patients with bipolar disorder 
with no relapse, first-generation relatives with no onset 
and healthy controls). Among these, a subgroup of 60 
patients, 60 healthy relatives (ultra risk) and 30 healthy 
individuals without a family history of affective disorders 
(healthy controls) will undergo functional and structural 
MRI at these time points.
Neurocognitive testing
Within ‘cold’ cognition verbal learning/memory 
and executive function have been highlighted as the 
most suitable candidates for biomarkers of bipolar 
disorder.83 84 ‘Cold’ cognition will therefore be assessed 
with neurocognitive tests probing verbal memory, atten-
tion and executive function including the Rey Auditory 
Verbal Learning Test85 86 and the WAIS-III letter-number 
sequencing, RBANS digit span, n-back working memory, 
verbal fluency and Trail Making Test B. Verbal intelli-
gence will be estimated with the Danish Adult Reading 
Test.
‘Hot’ cognition will be assessed with a comprehensive 
battery of computerised neurocognitive tests outside the 
scanner probing (1) emotional processing, (2) reward 
processing and (3) emotion regulation. These include the 
facial expression recognition and faces using dot-probe 
tasks from the Emotional Test Battery (P1Vital, Oxford), 
and an ecologically valid social scenarios test developed 
by our group.87 During fMRI we will also administer the 
following experimental paradigms: (1) an emotional 
face processing task using face stimuli from the Nimstim 
(http://www. macbrain. org/ resources. htm), (2) a mone-
tary reward processing task88 and (3) a negative affective 
picture task using validated stimuli sets from the Interna-
tional Affective Picture System developed in collaboration 
with researchers at the University of Chicago. In addition, 
we will explore the neuronal basis for ‘cold’ cognition 
(executive function) using n-back working memory and 
picture encoding tasks programmed in-house.89 Finally, 
self-report measures (BIS/BAS, and the CERQ90) are used 
to assess reward responsiveness and habitual emotional 
regulation strategies.
Structural MRI and fMRI
Structural MRI
Using T1-weighted images acquired at a 3T Siemens 
scanner at the Copenhagen University Hospital, Rigshos-
pitalet, we will focus on lateral ventricular volumes, 
grey matter volume of prefrontal cortex, amygdala and 
hippocampus, relative to whole brain volume. Specif-
ically, segmentation and analysis of subcortical and 
regional cortical volume, shape and grey matter density 
will be conducted with FMRIB Software Library (FSL) 
tools, including the FMRIB's Integrated Registration and 
Segmentation Tool, the FSL-VBM tool and FSL vertex 
(shape) analysis (http:// fsl. fmrib. ox. ac. uk/).
Functional MRI
T2-weighted images will be acquired to investigate white 
matter hyperintensities. We will also use fMRI to investi-
gate neuronal underpinnings of ‘hot’ and ‘cold’ cognition 
with the previously described experimental paradigms. 
fMRI data processing will be carried out with the FMRI 
Expert Analysis Tool, part of FMRIB's Software Library 
(www. fmrib. ox. ac. uk/ fsl). We will examine mean per cent 
BOLD signal change within predefined hippocampal and 
amygdala regions of interest obtained in standard space 
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with mri3dX (http://www. idoimaging. com/ program/ 
160). In addition, whole-brain exploratory analysis will 
be conducted to explore neural activity differences in 
other cortical regions. For this group analysis, individual 
contrasts of interest will be included in separate general 
linear models with non-parametric permutation inference 
(n=5000) using the ‘randomize’ algorithm implemented 
in FSL.91
Statistical power
The above sample size for participants undergoing fMRI 
assessments is determined based on our previous fMRI 
studies. In particular, inclusion of about 17–22 partic-
ipants per treatment/diagnostic group (matched for 
age and gender) had a power of >0.8 to detect differ-
ences between groups in neural and cognitive response 
to emotional faces (eg, refs 92 93 and Miskowiak et al, 
under review) at an alpha level of p<0.05 for cross-sec-
tional designs. For longitudinal designs, we were able to 
demonstrate differences between groups in the change in 
task-related neural activity and in hippocampal structure 
with a sample of about 40 participants per group.94–96 
Given this, our inclusion of 60 participants per group is 
expected to ensure adequate statistical power for both the 
cross-sectional and longitudinal parts of the fMRI study.
BIo-4: at risk or prodromal phase for bipolar disorder
Aims
To test whether (1) the composite blood-based biomarker, 
(2) the composite electronic smartphone-based 
biomarker and (3) the neurocognitive signature for 
bipolar disorder predict onset of illness (depression or 
mania) among a healthy (ie, non-syndromal level) high-
risk population of first-degree siblings and offspring to 
the patients with newly diagnosed/first-episode mania/
bipolar disorder, included in BIO-1, BIO-2 and BIO-3.
Background and theoretical basis
First-generation relatives to patients with bipolar disorder 
have a ninefold increased risk of developing bipolar 
disorder and a twofold to threefold increased risk of 
developing unipolar disorder.1 Although there is a great 
need for early detection and primary prevention of 
onset of illness among relatives to patients with bipolar 
disorder, recent prior attempts have not been successful 
due to retrospective designs, poor characterisation of 
high-risk individuals and small sample sizes.97 This is the 
first time a composite blood-based, a composite smart-
phone-based and a composite neurocognitive biomarker 
identified among patients with bipolar disorder will be 
investigated among their healthy relatives as a predictor 
measure of onset of illness.18 This approach increases the 
chances of obtaining a high specificity and sensitivity of 
the composite biomarkers.
Methods
This BIO-4 includes first-generation relatives (siblings 
and offspring aged 15–40 years) to the recruited patients 
with first manic or bipolar diagnosis. All recruited patients 
will be asked about the lifetime psychiatric history of 
first-degree relatives (their biological parents, siblings 
and offspring) based on the Brief Screening for Family 
Psychiatric History questionnaire described by Weissman 
and colleagues.98 We expect that at least 200 first-gen-
eration relatives will be asymptomatic or present mild 
symptoms or prodromal patterns to affective disorders 
and will be included in the study. Biological tissues will 
be drawn (as part of BIO-1) and neurocognitive function 
will be assessed on all individuals and brain imaging will 
be done on 60 individuals with longitudinal assessments.
Statistical analyses
BIO-4 will use a combination of penalised regression 
techniques, and random forests to infer the importance 
of the original and combined markers and to compare 
the similarity of prediction error from the models with 
and without combining the markers.
Feasibility
The BIO study is fully feasible as patients are recruited 
as part of daily healthcare for patients referred to the 
Copenhagen Affective Disorder Clinic.
ethical considerations
The BIO study has been approved by the Local Ethical 
Committee (H-7-2014-007) and the data agency, Capital 
Region of Copenhagen (RHP-2015–023). According to 
these specifications, adolescents aged 15–18 years will 
be invited only if parents have given consent. Data will 
be saved, encrypted and assessed according to the regu-
lations from the Capital Region of Denmark. The study 
complies with the Declaration of Helsinki principles 
(Seoul, October 2008).
dissemination
Study results will be presented in peer-reviewed journals 
and at international conferences in accordance with rele-
vant reporting guidelines.99 100
dIscussIon
summary
It is expected that the BIO cohort will provide valid 
biological, electronic, neurocognitive and neuroimaging 
data and for the first time longitudinally identify changes 
in biomarkers during different stages of bipolar illness, 
that is, at risk stage, following onset, during first relapse 
and recurrent relapses and in the late stages of the illness 
as according to Berk et al.15
limitations
Some limitations of the BIO study should be noted 
beforehand. First, the rather extensive initial assessment 
study procedure may potentially result in selection of 
participants who are intrinsically positive towards clinical 
research and readily willing to cooperate. Nevertheless, we 
expect that such selection will be decreased as it is likely 
that the vast majority of more than 100 newly diagnosed/
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first-episode patients with bipolar disorder referred to 
the Copenhagen Affective Disorder Clinic each year will 
accept participation in the BIO study as this implies an 
extensive clinical evaluation.
Second, attrition may increase during long-term 
follow-up and patients who stay in the study may adhere 
more to treatment in general. Such selection is inherent 
in clinical longitudinal research, and the large number 
of participants that will be included will increase external 
validity. Third, potential confounding effects of psycho-
tropic medication may influence comparisons between 
patients with bipolar disorder and healthy control indi-
viduals as well as comparisons within patients as the 
vast majority of patients will get medication that may 
change during the course of illness. Lithium, mood 
stabilisers and antipsychotics may have effects on the 
collected biological, smartphone-based, neuropsycho-
logical and brain imaging data. Effects of medication 
on biological measures are not clear101 although anal-
yses from systematic reviews and meta-analyses involving 
only patients with bipolar disorder have not found clear 
effects of medication on cytokines,34 35 BDNF37 and gene 
expression36 nor have subsequent individual studies on 
cytokines,44 102 BDNF,39 102 gene expression46 or DNA and 
RNA damage.40 41 Effects of medication on electronic 
smartphone-generated data as well as on neuropsycholog-
ical and brain imaging data are poorly investigated and 
warrant further studies.103
Fourth, due to the large number of biological and 
statistical tests included in the BIO study, chance find-
ings may occur in relation to the individual biological 
test. However, the aim of the BIO study is to identify a 
composite biomarker measure related to bipolar illness, 
depression and mania using cross validation or alter-
natively split sample designs in the development and 
validation of the composite biomarker.
Finally, the BIO study does not include (randomised) 
interventions limiting causal interpretations of the 
results. Nevertheless, with the BIO prospective, repeated 
measures design it is possible to identify valid associations 
between the composite measures (of biological, elec-
tronic, neuropsychological and brain imaging data) and 
depressive and manic symptoms and states.
strengths
The BIO study is the first study aiming to identify (1) 
a composite blood-based biomarker, (2) a composite 
electronic smartphone-based biomarker and (3) a 
neurocognitive signature for bipolar disorder as well as 
to measure the same biomarkers in newly diagnosed/
first-episode patients with bipolar disorder and their 
healthy first-generation relatives. It is possible to recruit 
newly diagnosed/first-episode patients with mania/
bipolar disorder as all such patients from the entire 
Capital Region of Denmark are referred to the Copen-
hagen Affective Disorder Clinic and routinely asked 
for inclusion in the BIO study. Long-term attrition is 
supposed to be low as all patients will be followed by 
the Copenhagen Affective Disorder Clinic for the first 
2 years and subsequently in other treatment settings in 
the Capital Region of Denmark. Including longitudinal 
assessment of healthy individuals is of paramount impor-
tance to control for the effect of timing and ageing,104 but 
among all studies on biomarkers in bipolar disorder, this 
has been done only in two studies from our group.40 44 
The study will be performed by an experienced interna-
tional research group, combining expertise from all areas 
of the study.
conclusIon
The BIO study is a large long-term cohort study on 
biomarkers in bipolar disorder and we expect that 
the findings for the first time will be representative of 
biomarkers in bipolar disorder in general as no prior 
study on newly diagnosed/first-episode bipolar disorder 
has been conducted. It is expected that the BIO cohort 
will provide valid biological, electronic, neuropsycholog-
ical and brain imaging longitudinal data.
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